Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore - ARCATUS®, Branded as XIPERE® in the U.S., is the First Globally Approved Suprachoroidal Therapy - - Continued Global Expansion of Clearside’s Suprachoroidal Space Injection Platform Featuring...

Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema - Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China - - Agreement Provides Additional Validation for Clearside’s Suprachoroidal Space...